Everest Medicines (HKEX 1952.HK) announced the closing of its previously announced exclusive licensing and collaboration agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX) for the development and commercialization of civorebrutinib (also…
Avantor, a leading global provider of mission-critical products and services to the life sciences and advanced technology industries,announced today it has been appointed the exclusive distributor of Sartorius Filter Papers…
June 26, 2026, Everest Medicines today announced that China’s National Medical Products Administration (NMPA) accepted the Biologics License Application (BLA) for LEROCHOL(R) (lerodalcibep), a third-generation PCSK9 inhibitor, for subcutaneous use…
Everest Medicines (HKEX 1952.HK) announced that Everest Medicines and Hainan Herui have entered into a commercialization collaboration relating to Hainan Herui’s budesonide enteric capsules, which were approved by the National…
China Medical System Holdings Limited (867.HK/8A8.SG) (CMS, or the Group) is pleased to announce that, the New Drug Application for Silevimig Injection (GR1801, the Product), a Class 1 therapeutic biological…
Everest Medicines (HKEX 1952.HK)announced that it has entered into an exclusive licensing agreement with Australia Dimerix Limited (Dimerix), for the development and commercialization of DMX-200 in Greater China (Chinese mainland,…
Everest Medicines today announced that it has entered into an exclusive licensing agreement with Jiangsu Vcare PharmaTech Co., Ltd. (“Vcare”), for the development, registration and commercialization of Sumecigrel (formerly known…
Hua Medicine (“the Company”, stock code: 2552.HK) presented a series of breakthrough research findings on dorzagliatin (Trade name: HuaTangNing, Trade name in Hong Kong: MYHOMSIS(R)), the world’s first-in-class glucokinase activator…
HighTide Therapeutics, Inc. (HKG: 2511), an innovative biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for cardiovascular–kidney–metabolic (CKM) diseases, today presented new findings on the renoprotective effects of…
Everest Medicines (HKEX 1952.HK) announced that it has entered into a commercialization license agreement with Beijing Mabworks Biotech Co., Ltd. (Mabworks), under which the Company has obtained exclusive rights for…
Everest Medicines (HKEX 1952.HK) announced that it has entered into an exclusive licensing and collaboration agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX) for the development and commercialization of civorebrutinib (also…
Everest Medicines (HKG: 1952) announced that on 14 May 2026, based on strong confidence in the company’s future prospects and long-term development, Mr. Wei Fu, a non-executive Director, the honorary…
Over 1,000 investment and business matching meetings, MoUs to support healthcare enterprises to go global The sixth Asia Summit on Global Health (ASGH), jointly organised by the Government of the…
SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”; stock code: 03681.HK) is pleased to announce that Dr. Shui On Leung, Executive Director, Chairman and Chief…
ASGH and Medical Fair open concurrently, showcasing cutting-edge AI, Robotics and MedTech The fifth International Healthcare Week (IHW), organised by the Hong Kong Trade Development Council (HKTDC), opens today, featuring…
Holista Colltech Limited (ASX: HCT) (Holista or the Company) is pleased to announce that it has entered into a binding Joint Venture Agreement with Swang Chai Chuan Limited (HKEX: 2321)…
HONG KONG, Apr 28, 2026 – (ACN Newswire) – Driven by the continuous innovation in global biopharmaceutical technology, the steady rollout of favorable policies, and escalating clinical demands, the biopharmaceutical…
China Medical System Holdings Limited (CMS or the Group) is pleased to announce that, the Group through its wholly-owned subsidiary entered into an exclusive commercialization and supply agreement (the Agreement)…
China Medical System Holdings Limited (the Group or CMS) is pleased to announce that the New Drug Application (NDA) in China for the Seasonal Allergic Rhinitis (SAR) indication of MG-K10…
HONG KONG, Apr 22, 2026 – (ACN Newswire) – Hengrui Pharma reported steady growth in the first quarter of 2026. In Q1 2026, the Company recorded revenue of RMB 8.14…
